Page last updated: 2024-08-23

haloperidol decanoate and Basal Ganglia Diseases

haloperidol decanoate has been researched along with Basal Ganglia Diseases in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (40.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bošković, M; Grabnar, I; Kores Plesničar, B; Terzič, T; Vovk, T	1
Glick, ID; Marder, SR	1
Eklund, K; Forsman, A	1
Kissling, W; Möller, HJ	1
Elderson, A; Verhoeven, WM; Westenberg, HG	1

Trials

2 trial(s) available for haloperidol decanoate and Basal Ganglia Diseases

Article	Year
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:5 Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Female; Haloperidol; Humans; Incidence; Injections, Intramuscular; Long-Term Care; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Treatment Outcome	2005
Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo. Clinical neuropharmacology, 1991, Volume: 14 Suppl 2 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychiatric Status Rating Scales; Radioimmunoassay; Recurrence; Schizophrenia	1991

Article

Year

Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.

The Journal of clinical psychiatry, 2005, Volume: 66, Issue:5

Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Female; Haloperidol; Humans; Incidence; Injections, Intramuscular; Long-Term Care; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Treatment Outcome

2005

Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.

Clinical neuropharmacology, 1991, Volume: 14 Suppl 2

Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychiatric Status Rating Scales; Radioimmunoassay; Recurrence; Schizophrenia

1991

Other Studies

3 other study(ies) available for haloperidol decanoate and Basal Ganglia Diseases

Article	Year
Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate. Psychiatry research, 2013, Dec-30, Volume: 210, Issue:3 Topics: Adult; Antioxidants; Antipsychotic Agents; Basal Ganglia Diseases; Catalase; Female; Glutathione; Glutathione Peroxidase; Haloperidol; Humans; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Psychopathology; Schizophrenia; Severity of Illness Index; Superoxide Dismutase	2013
Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics. Clinical neuropharmacology, 1986, Volume: 9 Suppl 4 Topics: Administration, Oral; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Delayed-Action Preparations; Haloperidol; Humans; Maintenance; Schizophrenia	1986
Neuroleptic malignant syndrome: successful treatment with bromocriptine. Biological psychiatry, 1985, Volume: 20, Issue:6 Topics: Adolescent; Basal Ganglia Diseases; Bromocriptine; Creatine Kinase; Haloperidol; Homovanillic Acid; Humans; Male; Neuroleptic Malignant Syndrome; Paranoid Disorders; Prolactin; Transaminases	1985